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Abstract
Background and Objective Although the separate effects of drug–drug interactions and pregnancy on antiretroviral drug 
pharmacokinetics have been widely studied and described, their combined effect is largely unknown. Physiological changes 
during pregnancy may change the extent or clinical relevance of a drug–drug interaction in a pregnant woman. This review 
aims to provide a detailed overview of the mechanisms, magnitude, and clinical significance of antiretroviral drug–drug 
interactions in pregnant women.
Methods We performed a literature search and selected studies that compared the magnitude of drug–drug interactions with 
antiretroviral drugs in pregnant vs non-pregnant women.
Results Forty-eight papers examining drug–drug interactions during pregnancy were selected, of which the majority focused 
on pharmacokinetic boosting. Other selected studies examined the drug–drug interactions between efavirenz and lumefan-
trine, efavirenz and tuberculosis drugs, etravirine and tenofovir disoproxil fumarate, atazanavir and tenofovir disoproxil, 
and mefloquine and nevirapine in pregnant compared to non-pregnant women. The clinical significance of antiretroviral 
drug–drug interactions changed during pregnancy from a minimal effect to a contra-indication. In almost all cases, the clinical 
significance of a drug–drug interaction was more relevant in pregnant women, owing to the combined effects of pregnancy-
induced physiological changes and drug–drug interactions leading to a lower absolute drug exposure.
Conclusions Multiple studies show that the clinical relevance of a drug–drug interaction can change during pregnancy. 
Unfortunately, many potential interactions have not been studied in pregnancy, which may place pregnant women living 
with human immunodeficiency virus and their newborns at risk.
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Key Points 
More attention is needed from both researchers and 
clinicians to demonstrate which drug–drug interactions 
(DDIs) are clinically relevant in special populations.
The extent of a DDI may differ if the exposure of the 
perpetrator changes during pregnancy. DDIs at the level 
of intestinal transporters do not seem to be different in 
pregnant women.
The clinical significance of most DDIs in this review 
changed during pregnancy when looking at the absolute 
drug exposure in pregnant women. The combined effects 
of the DDI and other pregnancy-related physiological 
changes may lead to a more pronounced reduction in 
drug exposure, thereby exposing to the risk of therapeu-
tic failure.
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1 Introduction
All patients living with human immunodeficiency virus 
(HIV) must be exposed to an adequate concentration of 
antiretroviral drugs (ARVs) to achieve and maintain viro-
logic suppression. In pregnancy, the exposure, and thus the 
efficacy of ARVs, can be modified by several factors such 
as drug–drug interactions (DDIs) and pregnancy-induced 
physiological changes. These factors have to be taken into 
consideration when selecting an individual ARV regimen in 
addition to side effects, resistance testing, previous antiviral 
regimens, and practical aspects [1].
Several studies have demonstrated the clinically relevant 
effect of DDIs on the pharmacokinetics of ARVs. Protease 
inhibitors (PIs), non-nucleoside reverse transcriptase inhibi-
tors, and the integrase strand inhibitor (INSTI) elvitegravir 
(EVG) are extensively metabolized by the cytochrome P450 
enzyme (CYP450) system leading to a variety of relevant 
DDIs [2, 3]. For example, the exposure of multiple ARVs 
is decreased as a result of CYP induction by rifampicin [4]. 
However, ARVs can also influence other co-medications: 
efavirenz (EFV) induces CYP3A4 activity and can, thereby, 
decrease the efficacy of several co-medications [5]. We also 
make use of interactive effects, for example CYP3A4 inhibi-
tion by ritonavir or cobicistat to increase the exposure to PIs 
and EVG (pharmacokinetic boosting) [6]. Drug–drug inter-
actions are not limited to CYP interactions, but extend to 
non-CYP metabolism, drug transporters, and the absorption, 
distribution, and elimination of drugs. Inhibition of efflux 
transporter proteins in the gastrointestinal tract by cobicistat 
can increase the absorption of substrates of this transporter 
[7]. Drug absorption can also be affected by chelation with 
another drug and by pH-influencing drugs [8, 9]. Plasma 
protein displacement can affect the total plasma concentra-
tion and distribution of some highly protein-bound drugs 
[10].
It is also clearly demonstrated that physiological changes 
in pregnancy influence the pharmacokinetics of ARVs 
and co-medications [11]. Drug absorption may be altered 
because of increased gastric pH and slower intestinal motil-
ity [12, 13]. Physiological processes affect the ARV distri-
bution and changes in plasma protein concentrations can 
affect the unbound ARV fraction of highly protein-bound 
drugs [14]. Finally, changes in hepatic blood flow, metabolic 
enzyme activity, glomerular filtration rate, and renal blood 
flow may alter the metabolism and elimination of ARVs and 
co-medication [14, 15].
In general, dosing recommendations and contra-indica-
tions of ARVs are based on DDI studies in healthy volun-
teers or individuals living with HIV, while pregnant women 
are excluded. However, pregnancy-related physiological 
changes may influence the magnitude or clinical relevance 
of a DDI. A non-clinically relevant DDI leading to a margin-
ally lower exposure of the ARV in a non-pregnant woman 
may become relevant when adding the effect of pregnancy 
causing a potential risk for virologic failure and mother-
to-child transmission. As an example, labels were recently 
updated to discourage the use of cobicistat-boosted regimens 
during pregnancy owing to a reduced exposure of cobicistat 
leading to insufficient concentrations of the boosted ARV 
during pregnancy, whereas this effect is not observed in non-
pregnant women [16].
Antiretroviral drug exposure is difficult to predict in preg-
nant women, especially when the women are receiving inter-
acting co-medications. The ARV exposure is determined by 
the different pharmacokinetic processes in the body. A phar-
macokinetic process, for example hepatic metabolism by 
CYP3A4 enzymes, can be influenced by a DDI and physio-
logical pregnancy changes concurrently. Pregnancy hormones 
induce CYP3A4 activity, while an interacting drug can inhibit 
CYP3A4 activity [14]. This is further complicated if the DDI 
degree is concentration dependent because the concentration 
of the interacting drug can be impacted by the DDI itself and 
by the physiological changes related to pregnancy. These 
interrelated effects make it difficult to predict the magnitude 
of DDIs in pregnant women, and studies examining DDIs in 
pregnant women are, therefore, necessary to ensure adequate 
ARV exposure and efficacy. This article provides an overview 
of the current knowledge on DDIs with ARVs in pregnant 
women living with HIV. The inter-related effects of DDIs and 
physiological changes in pregnancy are further elucidated in 
the results section with the examples from the literature. We 
discuss the mechanisms leading to altered ARV exposure and 
the effect in terms of clinical relevance.
2  Search Methodology
PubMed and Embase searches were performed to find the 
relevant articles about DDIs in pregnant women living with 
HIV. The following terms were used: (Pregnancy OR preg-
nant) AND drug interaction* AND anti human immuno-
deficiency virus agents. As boosting is not always referred 
to as being an interaction, a second search term was used: 
‘Pharmacokinetic*’ AND ‘HIV’ AND ‘pregnant OR preg-
nancy’ AND ‘ritonavir OR cobicistat’. In addition, regis-
tration information from the European Medicines Agency 
and the US Food and Drug Administration was used and 
abstracts of relevant international conferences (Conference 
on Retroviruses and Opportunistic Infections, International 
Workshop on Clinical Pharmacology of Antiviral Therapy, 
European AIDS Conference and International AIDS Confer-
ence) were screened.
We selected studies comparing drug exposure in pregnant 
women with exposure in women postpartum or non-preg-
nant women. Drug–drug interactions in pregnant women 
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are discussed for enzyme inhibition, enzyme induction, 
transporter inhibition, and for other unknown mechanisms. 
For every interaction mechanism, three scenarios are dis-
cussed: (1) the effect of DDIs in non-pregnant individuals 
(mostly studied in men); (2) the effect of pregnancy on drug 
exposure in the absence of an interacting drug; and (3) the 
combined effect of DDIs and pregnancy on drug exposure in 
pregnant women. In addition, changes in the DDI magnitude 
and the related clinical significance in pregnant women are 
discussed.
3  Studied Interactions in Pregnant Women 
Living with HIV
In total, 48 relevant papers and abstracts were selected. 
The majority of these studies examined the DDI between a 
booster and PIs or EVG in pregnant compared to postpartum 
women. Other selected studies examined the DDI between 
EFV and lumefantrine (LF) [n = 1], EFV and tuberculosis 
drugs (n = 1), etravirine (ETR) and tenofovir disoproxil 
fumarate (TDF) [n = 1], tenofovir alafenamide (TAF) and 
cobicistat (n = 2), atazanavir (ATV) and TDF (n = 3), and 
mefloquine and nevirapine [n = 1] in pregnant compared to 
non-pregnant women.
3.1  Enzyme Inhibition
3.1.1  Boosters and Protease Inhibitors/Elvitegravir
The DDI between boosters (i.e., cobicistat and ritonavir) 
and PIs/EVG has been extensively studied in pregnant 
women living with HIV. The effect of pregnancy-related 
physiological changes on the DDI was evaluated by com-
paring the PI/EVG exposure during pregnancy and post-
partum in the same women. A decreased PI/EVG exposure 
was repeatedly confirmed in pregnant women during the 
first, second, and third trimester compared to postpartum. 
The average area under the curve (AUC) decrease had 
a range of 5–56% for PIs and 7–44% for EVG (Table 1) 
[17–53].
Figure 1 discusses the mechanism of this DDI in pregnant 
women considering three scenarios, which all compare to 
non-pregnant women using PIs or EVG without boosters. 
Figure 1a depicts the DDI in the non-pregnant situation 
where the PI/EVG exposure is greatly increased owing to 
CYP3A4 inhibition by the booster [54–56]. Figure 1b shows 
the probable effect of pregnancy on PI/EVG and booster 
exposures in the absence of the DDI. Hormonal changes in 
pregnancy induce CYP3A4 activity, which results, likely in 
combination with other physiological pregnancy changes, 
in decreased PI/EVG and booster exposures [14]. Pharma-
cokinetic assessments of unboosted indinavir, a PI primarily 
metabolized by CYP3A4, have been performed in pregnant 
women living with HIV, mimicking the situation in Fig. 1b. 
These studies showed a 62–86% decrease in indinavir AUC 
0–8 h during pregnancy compared with postpartum [57–59]. 
In one study, the decreased indinavir exposure corresponded 
to an increase in the urinary metabolic ratio of cortisol, a 
reliable marker for CYP3A4 activity, supporting that 
induced CYP3A4 activity contributed to decreased PI/EVG 
exposure during pregnancy [59]. Another study reported the 
metabolic ratio of cortisol to be 35% (1–81%) [median (95% 
confidence interval [CI])] higher during the third trimester 
of pregnancy compared to postpartum [60].
As described in Fig. 1c and Table 1, the combined effects 
(pregnant women taking a boosted PI/EVG regimen) lead 
to lower PI/EVG exposures than non-pregnant women tak-
ing a boosted PI/EVG regimen. The median (range) boosted 
indinavir AUC 0–12 h was 27.1 (18.6–44.7) μg*h/mL during 
postpartum compared with 16.1 (7.5–39.9) μg*h/mL in the 
third trimester, showing a 40% decrease for ritonavir-boosted 
indinavir during pregnancy (Table 1) [41]. The ritonavir 
AUC 0–12 h was also decreased by 60% during pregnancy, 
as a result of both pregnancy-related CYP induction and of 
other physiological changes (i.e., decreased plasma albumin) 
[Fig. 1c, Table 1] [41, 46]. The comparison of unboosted and 
boosted indinavir pharmacokinetics shows that pregnancy 
has a smaller impact on ritonavir-boosted indinavir (~ 40%) 
than unboosted indinavir (62–86%) and that the absolute 
indinavir exposure is higher for ritonavir-boosted indinavir 
than for unboosted indinavir in pregnant women [41, 57–59]. 
This suggests that CYP3A4 inhibition by ritonavir, despite a 
reduction in ritonavir exposure during pregnancy, compen-
sates, to some extent, the CYP3A4 induction in pregnancy 
(Fig. 1c).
Physiological changes in pregnancy seem to have a differ-
ent effect on ritonavir- and cobicistat-boosted regimens, as 
shown in Table 1. The darunavir (DRV) trough concentration 
(Ctrough) seems to be particularly lower during pregnancy 
in cobicistat- compared to ritonavir-boosted DRV 800 mg 
once-daily regimens; boosting with cobicistat resulted in a 
71–92% decrease in Ctrough vs 24–64% with ritonavir boost-
ing [25, 26, 28–31, 33, 34]. Similarly, the ATV Ctrough is 
lower in cobicistat- compared to ritonavir-boosted regimens, 
and EVG Ctrough is also excessively decreased during preg-
nancy on average by 81–89% [17–24, 35–38]. Because of 
the pronounced reduction in Ctrough, which is considered to 
be mostly related to efficacy, cobicistat-boosted regimens are 
no longer recommended during pregnancy [16]. The differ-
ence in booster efficacy in pregnant women can be caused 
by multiple processes.
First, the decrease in cobicistat AUC and especially the 
Ctrough seems larger compared to the decrease in ritonavir 
AUC and Ctrough (Table 1). Cobicistat concentrations in preg-
nant women largely drop below the half maximal inhibitory 
concentration for CYP3A4 inhibition (i.e., 0.11 mg/L) to 
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trough concentrations < 0.05 mg/L during the dosing inter-
val [33, 35, 38, 61]. Cobicistat exposure is significantly 
decreased in the third trimester compared with non-pregnant 
women resulting in a decreased cobicistat-boosting effect 
[36]. Conversely, ritonavir trough concentrations in pregnant 
women do still exceed the half maximal inhibitory concen-
tration for CYP3A4 inhibition of 0.08 mg/L after twice-daily 
dosing [25, 39, 42, 43, 46, 48, 50, 51, 61, 62], although not 
after once-daily dosing [17, 19, 21, 22, 25, 28].
Second, ritonavir is a more robust booster as CYP3A4 
inhibition by ritonavir may last at reduced exposures. A dose 
reduction from 100 to 50 mg of ritonavir has been shown 
to cause no change in saquinavir concentrations and did not 
affect ATV concentrations (median [interquartile range] 
ATV Ctrough 0.13 [0.10–0.23] and 0.16 [0.11–0.21] mg/L for 
100 mg and 50 mg of ritonavir, respectively) [63, 64]. In con-
trast, a dose reduction from 150 to 100 mg in cobicistat has 
been shown to substantially influence ATV concentrations 
(mean [% coefficient of variation] ATV Ctau 0.13 [42.7%] 
and 0.08 [58.8%] mg/L for 150 mg and 100 mg of cobicistat, 
respectively) [65]. Boosting by ritonavir has also been shown 
to be more robust in the presence of inducers like ETR. No 
clinically significant DDI was observed when co-administer-
ing ETR with DRV/ritonavir whereas ETR caused a signifi-
cant decrease in DRV/cobicistat Ctrough [66–68].
Third, both boosters are highly protein bound, and 
for ritonavir similar unbound (“active”) concentrations 
have been repeatedly reported in pregnancy [22, 36, 46]. 
Despite a large decrease in total ritonavir concentrations, 
unbound ritonavir concentrations are similar in pregnancy, 
this indicates that the driver for altered total ritonavir 
concentrations is the altered protein binding in pregnancy 
[69]. For cobicistat, this is still unclear, but a case report 
suggests similar unbound cobicistat concentrations during 
pregnancy as well [36]. Altogether, available data suggest 
that ritonavir boosting is more robust during pregnancy 
compared with cobicistat.
Although there is a clinically different interaction in 
pregnant women taking a cobicistat-boosted regimen, 
some experts also believe that the result of pregnancy-
related physiological changes are clinically relevant for 
some ritonavir-boosted regimens [70, 71]. Alternative 
dosing regimens are recommended for ritonavir-boosted 
ATV, DRV, and lopinavir to ensure an adequate Ctrough 
during pregnancy [70, 71]. Because of the abundance of 
alternative regimens, no increased dose of EVG or addi-
tional cobicistat dosing has been evaluated in pregnant 
women treated with a cobicistat-boosted EVG-based regi-
men. However, it would be interesting to evaluate whether 
dosing modification of EVG or cobicistat leads to adequate 
EVG exposure during pregnancy.
3.2  Enzyme Induction
3.2.1  Efavirenz and Lumefantrine
Adegbola et al. examined the DDI between the antiretrovi-
ral EFV and the antimalarial LF in pregnant women com-
pared to women postpartum [72]. Lumefantrine is primarily 
metabolized by CYP3A4 and EFV induces CYP3A4 activ-
ity, resulting in a decreased LF exposure in non-pregnant 
patients as showed in Fig. 2a [72, 73]. Pregnant women 
treated with LF have ~ 30% lower LF concentrations at day 
7, a marker for therapeutic efficacy, compared with non-
pregnant women [74–77]. A higher metabolic or elimination 
rate was observed in some of the pharmacokinetic studies, 
indicating induced CYP3A4 activity during pregnancy [14, 
75–77]. Altered distribution of the lipophilic LF is also 
hypothesized to decrease LF exposure during pregnancy and 
is represented by other physiological changes in Fig. 2b [74]. 
The study of Adegbola et al. also showed that the EFV mid-
dose concentration (C12h) significantly decreased in preg-
nant women treated with EFV compared with non-pregnant 
women (median 1820 ng/mL vs 2760 ng/mL, respectively). 
CYP3A4 activity ↓↓↓ Exposure to PI/EVG ↑↑↑   
Exposure to 
PI/EVG  ↓ Pregnancy
A. Only interaction C. Pregnancy + interaction 
Booster
CYP3A4 activity ↑
Other physiological 
changes 
Pregnancy
Booster ↓-↓↓
CYP3A4 activity ↓    
Other physiological 
changes 
Exposure to 
PI/EVG ↑ - ↑↑    
**
*
***
B. Only pregnancy
Exposure to 
booster  ↓ - ↓↓
Pregnancy
CYP3A4 activity ↑
Other physiological 
changes 
?
?
?
?
Fig. 1  Hypothesis of the drug–drug interaction of protease inhibitors 
(PIs)/elvitegravir (EVG) and boosters in pregnant women explained 
using three situations. The depicted situations are in comparison to 
PI/EVG exposure in non-pregnant women without booster co-treat-
ment. a Co-treatment with boosters increases PI/EVG exposure in 
non-pregnant individuals. b Physiological changes by pregnancy are 
expected to decrease PI/EVG exposure, as well as booster exposure. 
c Co-treatment with a booster in pregnant women increases the PI/
EVG exposure, although less than in non-pregnant women because 
of a decreased booster exposure resulting in less cytochrome P450 
(CYP) 3A4 inhibition. indicates a positive effect, \  indicates a nega-
tive effect, — indicates causes, - -> indicates a decreased positive 
effect, --\-indicates a decreased negative effect, *, ** and *** show 
inter-related effects
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The largest study of EFV pharmacokinetics during preg-
nancy showed a more modest effect. The 24-h concentration 
was significantly and marginally lowered during pregnancy 
(geometric mean ratio [90% CI] 0.92 [0.77–1.09], p = 0.01), 
while no-effect on the AUC 0–24 h was seen (geometric mean 
ratio [90% CI] 1.09 [0.90–1.32]) [78]. This modest reduction 
in EFV pharmacokinetics is supported by other intensive 
pharmacokinetic studies and occurs possibly because of 
decreased plasma proteins or CYP2B6 induction as depicted 
in Fig. 2b [79, 80].
A smaller reduction in LF exposure is surprisingly 
observed in pregnant women compared with postpartum 
co-treated with EFV in the study of Adegbola et al. This 
suggests that the magnitude of the DDI is mitigated during 
pregnancy. The authors hypothesized that the reduced EFV 
exposure during pregnancy may lead to less CYP3A4 induc-
tion, as shown in Fig. 2c. This suggests that the decreased 
CYP3A4 induction by EFV is not compensated by the hor-
mone-related CYP3A4 induction in pregnancy (Fig. 2c). 
Although CYP3A4 induction by EFV has been showed 
to be concentration dependent, it is debated if the modest 
EFV during pregnancy leads to less induction of CYP3A4 
[81]. The lack of an appropriate control group in the study 
by Adegbola et al. may have led to an inadequate conclu-
sion. Efavirenz is primarily metabolized by CYP2B6 and 
the CYP2B6 metabolizer status of the pregnant and non-
pregnant control group was not determined. Possibly, the 
non-pregnant control group consisted of more CYP2B6 slow 
metabolizers leading to higher EFV concentrations, which is 
correlated with lower LF concentrations [82].
Importantly, a considerable proportion of pregnant 
women were shown to have a LF concentration 7 days post-
drug intake below the 280-ng/mL cut-off previously consid-
ered for LF therapeutic efficacy [82]. Thus, the DDI between 
EFV and LF remains clinically relevant in pregnant women.
3.2.2  Efavirenz plus an Anti‑Tuberculosis Drug: Additional 
Influence of Genotype
The CYP-metabolizing genotype may also influence the 
clinical significance of a DDI in pregnant women. This is 
illustrated by the example of EFV, isoniazid, and rifampicin. 
Efavirenz is metabolized predominantly by CYP2B6 and to 
a lesser extent by CYP2A6 and CYP3A4. Efavirenz plasma 
concentrations are highly variable, and most variability can 
be explained by the CYP2B6 genotype [83].
Co-treatment with rifampicin, a CYP inducer, was shown 
to decrease EFV concentrations modestly and to increase 
inter-patient variability as shown in Fig. 3a [83, 84]. The 
effect of rifampicin was shown to vary depending on the 
CYP2B6 genotype; in patients with an extensive CYP2B6 
genotype, rifampicin caused a larger DDI magnitude [85]. 
Current treatment guidelines suggest that a dose adjustment 
of EFV is not necessary in the general population [83]. In 
pregnant women, EFV exposure is modestly decreased likely 
as a result of CYP2B6 induction and decreased plasma pro-
teins and does not warrant a dose adjustment (Fig. 3b) [79, 
80]. However, Dooley et al. demonstrated that pregnant 
women with an extensive CYP2B6 genotype are at a par-
ticular high risk for low EFV concentrations [83] and, there-
fore, this special patient population might require an increase 
in EFV dose. The cumulative effects of rifampicin interac-
tion, physiological pregnancy alterations, and an extensive 
CYP2B6 genotype may result in a clinically relevant interac-
tion (Fig. 3d). It has been reported that 36% of the pregnant 
women treated with rifampicin, isoniazid, and EFV had a 
minimum concentration < 1 μg/mL, compared with 23% 
of the pregnant women not treated with tuberculosis drugs 
[83]. Thus, the modest DDI between EFV and rifampicin 
may become relevant in pregnant women with an extensive 
CYP2B6 genotype, justifying an EFV dose increase. Addi-
tionally, the magnitude of the EFV and rifampicin DDI may 
be increased as rifampicin exposure is modestly increased 
CYP3A4 ↑↑ Exposure to LF ↓↓    
Exposure to LF ↓↓ Pregnancy
A. Only interaction C. Pregnancy + interaction 
EFV
CYP3A4 ↑
Other physiological 
changes 
Pregnancy
EFV ↓
CYP3A4 ↑ ?   
Other physiological 
changes 
   Exposure to LF ↓ ?   
*
***
B. Only pregnancy
Exposure to 
EFV ↓ 
Pregnancy
CYP3A4 ↑
Other physiological 
changes 
?
?
?
Fig. 2  Hypothesis of the drug–drug interaction of efavirenz (EFV) 
and lumefantrine (LF) in pregnant women explained using three situ-
ations. The depicted situations are in comparison to EFV exposure in 
non-pregnant women without the drug–drug interaction. a Co-treat-
ment with EFV decreases LF exposure. b Physiological changes by 
pregnancy decrease LF exposure, as well as EFV exposure slightly. 
c Co-treatment with EFV in pregnant women decreases the LF expo-
sure less than in non-pregnant women because of a decreased EFV 
exposure. indicates a positive effect, \  indicates a negative effect, — 
indicates causes, - -> indicates a decreased positive effect, *, ** and 
*** show inter-related effects
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during pregnancy, possibly as a result of decreased clearance 
due to cholestatic changes [86].
Isoniazid, a CYP2A6 inhibitor, may further increase EFV 
concentrations in pregnant women with a CYP2B6 slow-
metabolizer genotype, as in this situation CYP2A6 metab-
olism becomes more relevant [83]. A median minimum 
concentration of 6.54 μg/mL has indeed been reported in 
co-infected pregnant women with a slow-metabolizer geno-
type receiving tuberculosis treatment, making EFV-related 
side effects of concern [83].
3.3  Transporter Inhibition
3.3.1  Etravirine and Tenofovir Disoproxil Fumarate: 
An Additional Compartment
Another pitfall is that additional interactions may exist dur-
ing pregnancy because an additional compartment is present 
in pregnant women: the fetus. Transplacental transport to 
the fetus is susceptible to DDIs. Research showed for exam-
ple that ETR inhibits placental ABC transporter BCRP 
(ABCG2) in vitro, and ritonavir inhibits several placental 
ABC transporters at physiological concentrations [87, 88]. 
Etravirine and ritonavir can, therefore, increase the fetal 
exposure of co-administered PIs or lamivudine, which are 
known substrates of the placental ABC transporters [88].
3.3.2  Cobicistat and Tenofovir Alafenamide
Although cobicistat is contraindicated in pregnancy since 
2018, we discuss this interaction as this provides insight into 
transporter interactions during pregnancy. Interaction data in 
pregnancy are available from prior to 2018. When combined 
with cobicistat, TAF exposure is strongly increased by the 
inhibition of efflux transporter proteins in the gastrointes-
tinal tract (i.e., P-glycoprotein and breast cancer resistance 
protein) as shown in Fig. 4a [7]. Therefore, a dose reduc-
tion from 25 to 10 mg of TAF is recommended in patients 
co-treated with cobicistat in fixed-dose combinations [89]. 
In contrast to this interaction, pregnancy-related physiologi-
cal changes decrease TAF exposure (Fig. 4b); TAF expo-
sure decreased by approximately 35% in the third trimester 
in women treated with 25 mg of unboosted TAF [53, 90]. 
This decrease probably does not result from an alteration in 
transporter activity as indicated by an animal study showing 
similar P-glycoprotein activity in pregnant and non-pregnant 
mice [14].
In the combined situation of pregnant women co-treated 
with cobicistat, there is a marginal and insignificant decrease 
in TAF exposure compared with postpartum, see Table 1 and 
Fig. 4c [53, 90, 91]. This suggests that the DDI compensates 
for the reduced exposure as a result of the physiological 
pregnancy changes (Fig. 4b). Theoretically, this is inconse-
quent because cobicistat exposure is greatly reduced during 
pregnancy, as mentioned earlier. Possibly the magnitude 
of the DDI is not influenced by physiological pregnancy 
changes and the decreased cobicistat exposure. The intesti-
nal transporter inhibition by cobicistat might be caused by 
local (intestinal) cobicistat concentrations, and to a lesser 
extent by (decreased) systemic cobicistat concentrations 
[92]. This inconsistency can also be explained by the large 
variability and uncertainty in these data because TAF plasma 
concentrations are difficult to measure and often below the 
limit of quantification. It is unclear yet whether the intra-
cellular concentration of the active tenofovir anabolite is 
sustained during pregnancy.
The clinical significance of the interaction between TAF 
and cobicistat is lower in pregnant compared with non-preg-
nant women. The exposure of TAF is similar in pregnant 
women co-treated with TAF 25 mg and cobicistat (median 
AUC 0–24 h 335 ng*h/mL [91]) and non-pregnant patients 
treated with TAF 25 mg (median AUC 0–24 h 308 ng*h/mL 
[93]), which is considered to be a safe and regular treatment 
option. Based on these limited data, TAF exposure is not 
clinically significantly altered in pregnant women co-treated 
with cobicistat.
CYP2B6 ↑ Exposure toEFV ↓
A. Only interaction B. Only pregnancy C. Pregnancy + interaction
RIF
Other physiological 
changes 
Pregnancy
CYP2B6 ↑ ?
Exposure to
EFV ↓
Pregnancy
RIF ↑
Other physiological 
changes 
*
Metabolism: 
CYP2B6 ↑↑?
Exposure to
EFV ↓↓ ?***
Other physiological 
changes 
Pregnancy
CYP2B6 ↑
Exposure to
RIF ↑
D. Pregnancy + interaction + extensive metabolizer 
Pregnancy
RIF ↑
Other physiological 
changes 
*
Metabolism: 
CYP2B6 ↑↑↑ ?
Extensive 
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EFV ↓↓↓ ?***
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?
Fig. 3  Hypothesis of the drug–drug interaction of efavirenz 
(EFV) and rifampicin (RIF) in pregnant women with an extensive 
cytochrome P450 (CYP) 2B6 genotype explained using four situa-
tions. The depicted situations are in comparison to EFV exposure in 
non-pregnant women without the drug–drug interaction. a Co-treat-
ment with RIF decreases EFV exposure. b Physiological changes 
by pregnancy decrease EFV exposure slightly, and increase RIF 
exposure slightly [86]. c Co-treatment with RIF in pregnant women 
decreases the EFV exposure more than in non-pregnant women. d 
Co-treatment with RIF in pregnant women and an extensive CYP2B6 
genotype decreases the EFV exposure even more, owing to a higher 
CYP metabolism activity. indicates a positive effect, \  indicates a 
negative effect, *, ** and *** show inter-related effects
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3.4  Unknown Mechanism
3.4.1  Tenofovir Disoproxil Fumarate and Atazanavir
Several studies examined the DDI between TDF and ATV in 
pregnant women. Most studies observed a ~ 25% decrease in 
ATV exposure in non-pregnant patients co-treated with TDF 
[94–96], but a non-altered ATV exposure was also observed 
in one study [97]. The mechanisms of this DDI is unknown 
until today. As tenofovir (TFV) is renally cleared and ATV 
undergoes CYP-mediated metabolism, an interaction at the 
biotransformation level is unlikely. The DDI could possibly 
occur at the absorption level as a result of induction of intes-
tinal P-glycoprotein by TFV or owing to a physiochemical 
interaction in the gut [94].
A decrease in ATV exposure has also been confirmed in 
pregnant women living with HIV, as shown in Table 2 and 
depicted in Fig. 5b [18–21]. The ATV exposure is likely 
decreased in pregnant women owing to a combination of 
decreased absorption, increased clearance, and reduced 
booster exposure [19]. Tenofovir exposure is also decreased 
during pregnancy because of an increased volume of distri-
bution and increased renal excretion [98, 99]. Three stud-
ies confirmed that the ATV exposure is lower in pregnant 
women treated with a TDF-based regimen compared with 
both non-pregnant women co-treated with a TDF-based regi-
men and pregnant women co-treated with a non TDF-based 
regimen, see Table 2 and Fig. 5c [18, 19, 21].
The magnitude of the DDI does not seem to change dur-
ing pregnancy based on our recent data and third-trimester 
data from Mirochnick et al. (Table 2) [18, 21]. Interestingly, 
the study of Kreitchmann et al. reports a change in the mag-
nitude of DDIs during pregnancy, which seems to relate to 
non-adherence in the non-TDF arm in this study [19]. Thus, 
the similar DDI magnitude in pregnant women, despite 
the reduced TFV exposure, suggests that this DDI is not 
concentration dependent. This supports the hypothesis of 
a local interacting effect of TDF on the absorption of ATV. 
Furthermore, if the DDI is not influenced by physiological 
changes in pregnancy, there is probably no competing effect 
of pregnancy and TFV on ATV absorption (Fig. 5c).
Although the extent of the interaction is similar in non-
pregnant and pregnant women, the cumulative effect of 
physiological pregnancy changes (Fig. 5c) and the DDI 
lead to a more clinically significant DDI during pregnancy. 
Lower ATV Ctrough is observed in pregnant women with the 
DDI; a geometric mean (95% CI) of 0.44 (0.31–0.62) mg/
mL is observed in pregnant women co-treated with ATV and 
TDF vs a geometric mean (95% CI) of 0.89 (0.59–1.32) mg/
mL in non-pregnant women co-treated with ATV and TDF. 
Nevertheless, co-treatment with ATV and TDF is not contra-
indicated during pregnancy because the observed Ctrough is 
not lower than the 0.15-mg/L cut-off value considered for 
therapeutic efficacy [100, 101].
3.4.2  Nevirapine and Mefloquine
Haaland et al. examined ARV plasma concentrations in a 
group of pregnant women living with HIV co-treated with 
mefloquine, which showed a high rate of mother-to-child 
transmission [102]. A significant reduction in median nevi-
rapine concentrations (approximately 25%) was observed in 
pregnant women receiving co-treatment with mefloquine, 
although the nevirapine concentrations remained above the 
previously reported target values to prevent HIV replica-
tion [102]. This reduction was not observed in pregnant 
women receiving nevirapine with placebo. The mechanism 
of this DDI remains unclear, and the DDI may be observed 
in pregnant women owing to pregnancy-related physiologi-
cal changes that could amplify the magnitude of the DDI. 
This interaction has never been examined in non-pregnant 
women, and, therefore, the magnitude of the DDI in the non-
pregnant situation is unknown. Despite adequate nevirapine 
trough concentrations, more mother-to-child transmissions 
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Efflux transporters ↓
Exposure to
TAF ↑↑ 
A. Only interaction B. Only pregnancy C. Pregnancy + interaction
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Other physiological 
changes 
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Fig. 4  Hypothesis of the drug–drug interaction of cobicistat and ten-
ofovir alafenamide (TAF) in pregnant women explained using three 
situations. The depicted situations are in comparison to TAF expo-
sure in non-pregnant women without co-treatment with boosters. a 
Co-treatment with cobicistat increases TAF exposure. b Physiologi-
cal changes by pregnancy decrease TAF exposure, as well as cobi-
cistat exposure. c Co-treatment with cobicistat in pregnant women 
increases the TAF exposure, but this increase is less than in non-preg-
nant women with a cobicistat-boosted regimen (situation 4A). indi-
cates a positive effect, \  indicates a negative effect, *, ** and *** 
show inter-related effects
1229Drug–Drug Interactions in HIV-Infected Pregnant Women
Ta
bl
e 
2 
 O
ve
rv
ie
w
 o
f r
ep
or
te
d 
ph
ar
m
ac
ok
in
et
ic
 p
ar
am
et
er
s o
f a
ta
za
na
vi
r (
A
TV
) i
n 
pr
eg
na
nt
 w
om
en
 c
om
pa
re
d 
to
 n
on
-p
re
gn
an
t w
om
en
 w
ith
 a
nd
 w
ith
ou
t t
en
of
ov
ir 
di
so
pr
ox
il 
fu
m
ar
at
e 
(T
D
F)
 c
o-
tre
at
m
en
t
AU
C
  a
re
a 
un
de
r t
he
 c
ur
ve
, C
I c
on
fid
en
ce
 in
te
rv
al
, C
m
ax
 m
ax
im
um
 c
on
ce
nt
ra
tio
n,
 C
m
in
 m
in
im
um
 c
on
ce
nt
ra
tio
n,
 C
tro
ug
h t
ro
ug
h 
co
nc
en
tra
tio
n,
 G
M
 g
eo
m
et
ric
 m
ea
n,
 H
IV
 h
um
an
 im
m
un
od
efi
ci
en
cy
 
vi
ru
s, 
IA
 in
te
ra
ct
io
n,
 IQ
 in
te
rq
ua
rti
le
 ra
ng
e,
 S
D
 st
an
da
rd
 d
ev
ia
tio
n,
 se
lf-
ca
lc
ul
at
ed
 ra
tio
 ra
tio
 o
f p
ub
lis
he
d 
m
ea
n 
va
lu
es
 c
al
cu
la
te
d 
by
 th
e 
au
th
or
s
Re
fe
re
nc
e
Po
pu
la
tio
n
Pa
ra
m
et
er
N
on
-p
re
gn
an
t i
nd
iv
id
ua
ls
/p
os
tp
ar
tu
m
 w
om
en
Pr
eg
na
nt
 w
om
en
W
ith
ou
t T
D
F
W
ith
 T
D
F
Se
lf-
ca
lc
ul
at
ed
 
ra
tio
W
ith
ou
t T
D
F
W
ith
 T
D
F
Se
lf-
ca
lc
u-
la
te
d 
ra
tio
Ta
bu
re
t e
t a
l. 
[9
4]
H
IV
-in
fe
ct
ed
 n
on
-p
re
gn
an
t p
at
ie
nt
s, 
n =
 11
, 
Fr
an
ce
, i
nt
en
si
ve
 sa
m
pl
in
g 
af
te
r 4
 w
ee
ks
 w
ith
 
A
TV
 a
nd
 2
 w
ee
ks
 c
o-
tre
at
m
en
t w
ith
 T
D
F,
 M
ea
n 
(S
D
)
A
U
C
 (h
*n
g/
L)
53
.8
 (3
5.
3)
39
.3
 (2
3.
0)
0.
73
C
m
ax
 (μ
g/
m
L)
5.
2 
(3
.0
)
3.
4 
(1
.4
)
0.
66
C
m
in
 (μ
g/
m
L)
0.
86
 (0
.8
)
0.
58
 (0
.4
)
0.
67
C
ol
be
rs
 e
t a
l. 
[1
8]
H
IV
-in
fe
ct
ed
 p
re
gn
an
t p
at
ie
nt
s, 
n =
 31
 (t
hi
rd
 
tri
m
es
te
r)
, n
 =
 25
 (p
os
tp
ar
tu
m
), 
52
%
 b
la
ck
, 
in
te
ns
iv
e 
sa
m
pl
in
g,
 fe
d,
 G
M
 (9
5%
 C
I)
A
U
C
 (h
*n
g/
L)
49
.2
 (3
4.
7–
69
.8
)
46
.1
 (3
6.
2–
58
.6
)
0.
94
32
.0
8 
(2
1.
1–
48
.7
)
28
.8
 (2
2.
2–
37
.4
)
0.
90
C
m
ax
 (μ
g/
m
L)
4.
58
 (3
.3
1–
6.
34
)
4.
17
 (3
.4
2–
5.
08
)
0.
91
2.
93
 (1
.9
5–
4.
40
)
2.
92
 (2
.2
1–
3.
84
)
1.
00
C
tro
ug
h (
μg
/m
L)
0.
90
 (0
.4
7–
1.
71
)
0.
89
 (0
.5
9–
1.
32
)
0.
99
0.
58
 (0
.3
2–
1.
05
)
0.
44
 (0
.3
1–
0.
62
)
0.
76
K
re
itc
hm
an
n 
et
 a
l. 
[1
9]
H
IV
-in
fe
ct
ed
 p
re
gn
an
t p
at
ie
nt
s, 
n =
 31
 (s
ec
on
d 
tri
m
es
te
r)
, n
 =
 68
 (p
os
tp
ar
tu
m
), 
44
%
 H
is
pa
ni
c,
 
in
te
ns
iv
e 
sa
m
pl
in
g,
 fe
d,
 M
ed
ia
n 
(I
Q
)
A
U
C
 (h
*n
g/
L)
48
.8
 (3
4.
9–
67
.5
)
58
.7
 (4
1.
4–
80
.5
)
1.
20
30
.6
 (1
9.
9–
39
.0
)
26
.2
 (1
9.
9–
38
.4
)
0.
86
C
m
ax
 (μ
g/
m
L)
4.
52
 (2
.3
1–
5.
61
)
5.
43
 (3
.8
1–
6.
80
)
1.
20
3.
11
 (1
.9
5–
4.
06
)
2.
73
 (1
.6
5–
4.
02
)
0.
88
C
tro
ug
h (
μg
/m
L)
0.
90
 (0
.3
9–
1.
33
)
1.
26
 (0
.6
9–
1.
95
)
1.
40
0.
71
 (0
.4
7–
1.
00
)
0.
44
 (0
.2
8–
0.
59
)
0.
62
M
iro
ch
ni
ck
 e
t a
l. 
[2
1]
H
IV
-in
fe
ct
ed
 p
re
gn
an
t p
at
ie
nt
s, 
n =
 38
 (t
hi
rd
 tr
i-
m
es
te
r)
, n
 =
 32
 (p
os
tp
ar
tu
m
), 
fe
d,
 M
ed
ia
n 
(I
Q
)
A
U
C
 (h
*n
g/
L)
57
.9
 (4
7.
1–
64
.8
)
39
.6
 (2
1–
54
.9
)
0.
68
41
.9
 (2
7.
4–
60
.8
)
28
.8
 (1
5.
4–
34
.5
)
0.
69
C
m
ax
 (μ
g/
m
L)
4.
1 
(3
–5
.8
)
4.
1 
(1
.7
–4
.5
)
1.
00
3.
6 
(2
.8
–5
.1
)
2.
5 
(1
.6
–3
)
0.
69
C
tro
ug
h (
μg
/m
L)
1.
2 
(1
.1
–2
)
0.
8 
(0
.6
–1
.2
)
0.
67
0.
7 
(0
.5
–1
.1
)
0.
5 
(0
.4
–0
.7
)
0.
71
1230 V. E. Bukkems et al.
were observed, making this DDI likely of clinical relevance 
for HIV and malaria co-infected pregnant women.
4  Common Unstudied Interactions 
in Pregnant Women Living with HIV
Other commonly used drugs in pregnancy that can interact 
with ARV include: proton pump inhibitors, iron and min-
eral supplements, antacids, domperidone, and macrolide 
antibiotics [103, 104]. Drug–drug interactions with these 
co-medications have not been studied in pregnant women, 
while having the potential for clinically relevant interactions. 
They also illustrate possibly altered interaction mechanisms 
during pregnancy at the level of distribution, absorption, and 
non-CYP metabolism.
For instance, caution is needed when interpreting serum 
concentrations of highly protein-bound ARVs (such as PIs 
and INSTIs) in pregnancy, especially when co-administered 
with other highly protein-bound drugs. A DDI at the level 
of distribution can theoretically change in pregnant women 
because the amount of plasma proteins decreases during 
pregnancy [14]. Competition for plasma proteins with a 
highly protein-bound concomitant drug and a decrease in 
plasma proteins can co-exist, resulting in even lower total 
ARV concentrations.
Another common DDI mechanism involves the chelation 
of INSTIs with divalent cations such as iron, requiring stag-
gered administration [8, 105–110]. The magnitude of the 
physiochemical interaction in the gut is not affected by phys-
iological changes in pregnancy. However, this DDI is likely 
to be more clinically relevant in pregnant women because 
of the additive effects of chelation and pregnancy-related 
physiological changes potentially leading to a lower abso-
lute INSTI exposure. Additionally, the time between INSTI 
and iron administration may need to be increased during 
pregnancy because gastrointestinal motility is decreased in 
pregnant women [14]. The limited decrease of raltegravir 
and dolutegravir (DTG) exposure in pregnant women is 
not considered to be of clinical significance [111–113], but 
may become of clinical significance in pregnant women co-
treated with iron.
Furthermore, the common DDI between gastric acid-
neutralizing drugs and ATV or rilpivirine (RPV) is yet 
unstudied in pregnant women living with HIV. The absorp-
tion of RPV/ATV decreases with increasing gastric pH, thus 
co-administration with proton pump inhibitors is contra-
indicated in non-pregnant women and it is recommended to 
stagger administration with histamine  H2 antagonists (cime-
tidine, famotidine, ranitidine) [96, 114]. However, a different 
recommendation might be needed in pregnant women as 
pregnancy-related physiological changes include a possible 
increase in gastric pH that will also result in a decrease in 
RPV/ATV exposure [13, 115–117]. Thus, it is possible that 
the absorption of ATV/RPV is worse in pregnant women 
treated with an  H2 antagonist because of the additive effect 
of the drug- and pregnancy-related physiological changes 
on the gastric pH. Research is needed to show if a contra-
indication for ATV/RPV and  H2 antagonists is required in 
pregnant women.
Hepatic DDIs concerning non-CYP enzymes can be 
potentially altered during pregnancy as well. A common 
example is the DDI between rifampicin and DTG, as the 
prevalence of HIV-tuberculosis co-infection is high in 
third-world countries and DTG-containing regimens are 
preferred according to the World Health Organization 
guidelines [118]. Glucuronidation to the main metabolite 
of DTG is catalyzed by UGT1A1, which can be induced by 
rifampicin. A dose increase to 50 mg of DTG twice daily is 
needed in non-pregnant individuals when co-administered 
with rifampicin [118, 119]. In pregnant women, DTG expo-
sure is modestly decreased and UGT1A1 induction and 
Absorption ATV ↓ Exposure to ATV ↓
A. Only interaction B. Only pregnancy C. Pregnancy + interaction
TDF
Other physiological 
changes 
Pregnancy
Absorption ATV ↓ ?
Exposure to
ATV ↓
Pregnancy
TDF / 
TFV ↓
Other physiological 
changes 
*Absorption ATV ↓ ?*
***
Physiological changes Pregnancy Exposure toTFV ↓
Exposure to
ATV ↓↓
? ?
? ?
?
?
?
Fig. 5  Hypothesis of the drug–drug interaction of tenofovir diso-
proxil fumarate (TDF) and atazanavir (ATV) in pregnant women 
explained using three situations. The depicted situations are in com-
parison to ATV exposure in non-pregnant women without tenofovir 
(TFV) co-administration. a Co-treatment with TDF decreases ATV 
exposure. b Physiological changes by pregnancy decrease ATV expo-
sure, as well as TFV exposure. c Co-treatment with TDF in pregnant 
women decreases the ATV exposure even more than in non-pregnant 
women because of the joined effects of the physiological changes in 
pregnancy and the interaction. The degree of interaction does not 
seem to change. indicates a positive effect, \ indicates a negative 
effect, --- indicates likely negligible effect, *, ** and *** show inter-
related effects
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decreased plasma proteins have been suggested as causes 
[111, 120, 121]. It is still uncertain if UGT1A1 is induced 
during pregnancy [14], as some studies suggested UGT1A1 
induction during pregnancy [122, 123], but an increased 
metabolic ratio of DTG-glucuronide/DTG could not be dem-
onstrated in a small pharmacokinetic study with pregnant 
women using DTG [120]. In pregnant women co-treated 
with DTG and rifampicin, the effect of physiological preg-
nancy alterations and rifampicin UGT1A1 induction could 
increase, leading to a larger decrease in DTG exposure than 
in pregnant women without rifampicin. A larger DTG dose 
increase may be needed in pregnant women co-treated with 
rifampicin and DTG, but a pharmacokinetic assessment is 
needed for confirmation.
5  Future Perspectives
More research on DDIs in pregnant women is needed, but the 
study design remains challenging. Pregnancy pharmacology 
studies lend themselves to investigate DDIs, as well as the 
systematic collection of therapeutic drug monitoring sam-
ples. In both cases, accurate registration of co-medication, 
dose, and time of intake make it possible to determine the 
absolute exposure of ARVs in pregnant women with DDIs, 
but a sufficient sample size is crucial for the interpretation. 
Observational pharmacology studies in pregnancy generally 
focus on the exposure to the ARV; however, in the presence 
of potential DDIs with non-ARVs, the plasma concentration 
of these agents should be systematically determined. Physi-
ologically based pharmacokinetic (PBPK) models have been 
applied to predict drug exposure in special populations and 
to simulate DDIs. The validity of pregnancy PBPK models 
has improved tremendously during the recent years owing 
to the increased interest in these models [124]. Although 
more in vitro and clinical studies are needed to fill knowl-
edge gaps, for example on UGT and drug transporter activ-
ity, the models are already widely used to understand and 
predict pharmacokinetic changes during pregnancy [124]. 
The knowledge from DDI and pregnancy PBPK models can 
be combined to improve our understanding of this complex 
situation. In particular, DDIs on the level of placental drug 
transport are difficult to investigate in clinical studies as only 
sampling from the umbilical cord during delivery is consid-
ered to be ethical. Knowledge on pregnancy PBPK models 
including the placenta and the fetus is gained rapidly and a 
combination of these models can offer a solution for predict-
ing placental drug transporter DDIs [125].
Clinically relevant DDIs apply to pregnant women, but 
are also a factor of consideration for other special patient 
population such as the elderly, children, and patients with 
hepatic impairment. The management of DDIs has to be 
conducted on an individual basis. In the era of precision 
medicine, DDIs cannot be ignored and are an opportunity 
for a more effective and individualized drug treatment. More 
attention is needed from both researchers and clinicians to 
demonstrate which DDIs are clinically relevant in special 
populations.
6  Conclusions
Drug–drug interactions in pregnant women remain a com-
plex situation because the extent and clinical significance 
of a DDI can change during pregnancy. Only a few studies 
examined this complex situation; therefore, the management 
of DDIs in pregnant women is mostly based on theoretical 
assumptions. This makes decisions regarding the optimal 
dose and ARV regimen very difficult, and places pregnant 
women living with HIV and their newborns at risk.
The extent of a DDI can change during pregnancy, 
although it is very challenging, if not impossible, to distin-
guish the influence of individual processes. The extent of a 
DDI may differ if the exposure of the perpetrator changes 
during pregnancy as suggested for concentration-dependent 
DDIs such as the DDI between cobicistat and PIs/EVG (inhi-
bition of metabolism). Drug–drug interactions at the level of 
intestinal transporters do not seem to be different in pregnant 
women (i.e., TAF co-administered with cobicistat).
More importantly, the clinical significance of most DDIs 
in this review changed during pregnancy when looking at the 
absolute drug exposure in pregnant women. The combined 
effects of the DDI and other pregnancy-related physiologi-
cal changes may lead to a more pronounced reduction in 
drug exposure, thereby exposing to the risk of therapeutic 
failure. Only the DDI between cobicistat and PIs/EVG in 
pregnancy has led to a change in drug labels; currently, 
the use of cobicistat-boosted regimens in pregnancy is no 
longer recommended [16]. There are not enough data for 
the other reviewed DDIs to change the official recommenda-
tions, although some DDIs resulted in drug concentrations 
below the target values in a large proportion of the pregnant 
women.
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